公开(公告)号：US11638711B2

公开(公告)日：2023-05-02

申请号：US16982281

申请日：2019-03-18

申请人： MC2 Therapeutics Limited

发明人： Nigel Crutchley ,  Michelle Georgiou ,  Stephen Lenon ,  Morten Praestegaard

IPC分类号： A61K31/4709 ,  A61K9/06 ,  A61K47/10 ,  A61K47/12 ,  A61P17/10 ,  A61P17/00 ,  A61P17/04 ,  A61P31/04 ,  A61K31/573 ,  A61K9/00 ,  A61K31/047 ,  A61K31/085 ,  A61K31/355 ,  A61K47/44

摘要： The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.

公开(公告)号：US11547722B2

公开(公告)日：2023-01-10

申请号：US16612885

申请日：2018-05-14

申请人： Jean-Jacques Walter

发明人： Jean-Jacques Walter

IPC分类号： A61K33/38 ,  A61P17/10 ,  A61K33/242 ,  A61K8/04 ,  A61K8/06 ,  A61K8/19 ,  A61K8/34 ,  A61K8/92 ,  A61K9/00 ,  A61K9/107 ,  A61K9/14 ,  A61K33/34 ,  A61K47/10 ,  A61K47/44 ,  A61K33/24

摘要： Disclosed are a composition containing a transition metal, as well as a method of treatment of bacterial, or of fungal diseases using such composition. The composition functions as novel bactericides and antifungal agents. The transition metal may be in either soluble or insoluble form.

公开(公告)号：US11518767B2

公开(公告)日：2022-12-06

申请号：US16907122

申请日：2020-06-19

申请人： GALDERMA RESEARCH & DEVELOPMENT

发明人： Laurence Clary ,  Jean-François Fournier ,  Gilles Ouvry ,  Yushma Bhurruth-Alcor ,  Etienne Thoreau ,  Loïc Tomas

IPC分类号： C07D487/20 ,  C07D487/04 ,  A61P17/00 ,  A61P17/06 ,  A61P35/00 ,  A61P17/10 ,  A61K9/00 ,  A61K31/519

摘要： The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.

公开(公告)号：US20220362212A1

公开(公告)日：2022-11-17

申请号：US17745823

申请日：2022-05-16

申请人： Skintech Life Science Limited

发明人： Michael C. SCAIFE

IPC分类号： A61K31/404 ,  A61P17/10 ,  A61K9/00 ,  A61K31/07

摘要： Described herein are methods for treating one or more skin conditions by administering, via the sublingual or buccal route, a composition comprising substituted or unsubstituted diindolylmethane. In particular, methods are provided for improving the bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following a sublingual or buccal administration, relative to an oral administration.

公开(公告)号：US20220331269A1

公开(公告)日：2022-10-20

申请号：US17856781

申请日：2022-07-01

申请人： Botanix Pharmaceuticals Ltd. ,  Botanix Pharmaceuticals, Inc.

发明人： Eugene R. Cooper ,  Matthew Callahan ,  Michael Thurn ,  David Dickason

IPC分类号： A61K31/08 ,  A61P17/10 ,  A61K9/00 ,  A61K9/08 ,  A61K47/10 ,  A61K47/24

摘要： A topical pharmaceutical composition comprising a solution of 2-(2-ethoxyethoxy)ethanol in a first solvent that is a 2-(2-ethoxyethoxy)ethanol solvent.

公开(公告)号：US11473093B2

公开(公告)日：2022-10-18

申请号：US17518960

申请日：2021-11-04

申请人： Eligo Bioscience

发明人： Aymeric Leveau ,  Inès Canadas Blasco ,  Aurélie Mathieu ,  Antoine Decrulle

IPC分类号： A61P17/10 ,  C12N15/76 ,  C12N15/11 ,  A61K39/02 ,  A61K39/05 ,  C12N9/22 ,  A61K39/00

摘要： The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.

公开(公告)号：US20220304920A1

公开(公告)日：2022-09-29

申请号：US17833304

申请日：2022-06-06

申请人： Locus IP Company, LLC

发明人： Sean FARMER ,  Ken ALIBEK

IPC分类号： A61K8/99 ,  A61K8/9794 ,  A61P17/10 ,  A61P17/02 ,  A61K8/34 ,  A61K8/66 ,  A61K8/73 ,  A61K8/81 ,  A61K9/00 ,  A61K31/05 ,  A61K31/728 ,  A61K35/74 ,  A61K36/062 ,  A61K38/47 ,  A61K45/06 ,  A61Q15/00 ,  A61Q19/00 ,  A61Q19/08 ,  A61K9/06 ,  A61K9/08 ,  A61Q19/02 ,  A61K9/107 ,  A61K9/10 ,  A61K9/12 ,  A61Q17/00 ,  A61Q5/00 ,  A61K8/64 ,  A61P17/12

摘要： The topical cosmetic compositions and methods of the subject invention can be used to treat and/or prevent a variety of skin conditions, including, for example, age spots, acne, scars, body odor, aging-related conditions (e.g., wrinkles, looseness and dryness), and scalp issues (e.g., dandruff, seborrheic dermatitis and hair loss). In preferred embodiments, the compositions according to the subject invention comprise biological amphiphilic molecules produced by microorganisms.

公开(公告)号：US20220274988A1

公开(公告)日：2022-09-01

申请号：US17746446

申请日：2022-05-17

申请人： Lutris Pharma Ltd.

发明人： Noa Shelach

IPC分类号： C07D473/00 ,  A61K9/00 ,  C07D401/14 ,  C07D401/10 ,  A61P17/10

摘要： The present invention discloses novel BRaf inhibitors, compositions comprising these BRaf inhibitors and uses thereof for the treatment, amelioration and/or prevention of cutaneous reactions.

公开(公告)号：US20220257625A1

公开(公告)日：2022-08-18

申请号：US17627474

申请日：2020-07-15

申请人： BIODERM, INC.

发明人： Lorraine Faxon Meisner

IPC分类号： A61K31/7008 ,  A61K9/00 ,  A61K33/00 ,  A61K31/375 ,  A61K31/05 ,  A61P17/02 ,  A61P17/10 ,  A61K31/198 ,  A61K47/46

摘要： The present disclosure provides compositions and methods of use thereof for the treatment of skin diseases and disorders or periodontal disease. The compositions comprise cannabidiol, derivatives or pharmaceutical salts thereof, and ascorbic acid. The formulations may also include an anti-inflammatory agent, such as glucosamine.

公开(公告)号：US20220257509A1

公开(公告)日：2022-08-18

申请号：US17666252

申请日：2022-02-07

申请人： GALDERMA HOLDING SA

发明人： Valerie JULIA ,  Jayendra Kumar KRISHNASWAMY

IPC分类号： A61K9/107 ,  A61K31/40 ,  A61P17/10

摘要： Disclosed herein are methods for treatment of a skin disorders using pharmaceutical compositions that reduces the expression of and/or inhibit the activity of various genes including chemokine (C-X-C motif) ligands such as CXCL13 and XCL1, and matrix-metalloproteinases such as MMP12 and MMP13. The pharmaceutical compositions effectively act on epidermal differentiation and proliferation as well as on innate and adaptive immune cells in pathogenesis of skin disorders such as acne.